drugset / Trial / NCT02225639

PRC-063 in an ADULT Workplace Environment

NCT02225639

RandomizedCrossoverTriple-blindTreatment

Summary

The primary objective of this study is to assess the time of onset and time course of efficacy over 16 hours of PRC-063 compared to placebo in adults diagnosed with ADHD in a simulated adult workplace environment (AWE) setting, as measured by the PERMP (an individually-adjusted math test) at pre-dose, 1.0, 2.0, 5.0, 8.0, 11.0, 14.0 and 16.0 hours post-dose.

Timeline

Start
2014-08
Primary completion
2015-04
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Methylphenidate Small molecule 25 mg Oral
Comparator Methylphenidate Small molecule 35 mg Oral
Comparator Methylphenidate Small molecule 45 mg Oral
Comparator Methylphenidate Small molecule 55 mg Oral
Comparator Methylphenidate Small molecule 70 mg Oral
Comparator Methylphenidate Small molecule 85 mg Oral
Comparator Methylphenidate Small molecule 100 mg Oral